| Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus. | |
| | |
MedLine Citation:
|
PMID: 22045829 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The effects of tesaglitazar on renal function (assessed as urinary clearance of (125)I-sodium iothalamate or estimated by the modification of diet in renal disease formula) were studied in a 24-week open-label trial in type 2 diabetes mellitus patients randomized to daily doses of either tesaglitazar 2 mg or pioglitazone 45 mg. The aim of the analysis was to develop a population pharmacokinetic-pharmacodynamic model that could simultaneously describe the interrelationship between tesaglitazar exposure and reduction in renal function over time in patients with type 2 diabetes mellitus. The pharmacokinetic-pharmacodynamic model could adequately describe the interplay between tesaglitazar and glomerular filtration rate. A one-compartment model in which the apparent clearance was influenced by glomerular filtration rate characterized the pharmacokinetics of tesaglitazar. An indirect-response model was used for the slow time course of change in glomerular filtration rate, which decreased from 100 to 78 mL/min/1.73m(2) after 12 weeks of treatment. All tesaglitazar-treated patients had a reduction in glomerular filtration rate, and available demographic variables could not explain differences in response. Patients treated with an angiotensin converting enzyme inhibitor were more sensitive to tesaglitazar and had larger glomerular filtration rate decrease compared to nontreated patients. Approximately 8 weeks after discontinuing treatment, mean glomerular filtration rate had returned towards baseline. The model and data give valuable insights into the dynamic changes in glomerular filtration rate over time. |
| | |
Authors:
|
Bengt Hamrén; K Peter Ohman; Maria K Svensson; Mats O Karlsson |
Related Documents
:
|
15830179 - Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-e... 16223549 - Obesity, diabetes and cognitive deficit: the framingham heart study. 10509609 - The yellow mouse obesity syndrome and mechanisms of agouti-induced obesity. 3361039 - Gynecologic-obstetric changes after loss of massive excess weight following bariatric s... 10923639 - Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in human... 22496559 - Diabetes impairs cortical plasticity and functional recovery following ischemic stroke. 3582599 - First degree family history of diabetes and risk factors for cardiovascular disease in ... 18176969 - A paradox: insulin inhibits expression and secretion of resistin which induces insulin ... 10485379 - Diabetic retinopathy after combined kidney-pancreas transplantation. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-1 |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: - ISSN: 1552-4604 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Uppsala University. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based S...
Next Document: Enhanced Sensitivity to Drug-Induced QT Interval Lengthening in Patients With Heart Failure Due to L...